{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-038073","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.798234+00:00","generated_at":"2026-06-17T10:12:43.210263+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023","bullets":["Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.","NDA submission for etripamil nasal spray in PSVT expected in Q3 2023; Phase 3 RAPID trial met primary endpoint (64.3% conversion vs 31.2% placebo).","Entered $125M strategic financing with RTW Investments: $50M convertible notes and $75M synthetic royalty commitment post-FDA approval.","Seth H.Z. Fischer appointed to Board of Directors effective March 21, 2023; brings commercial expertise from Johnson & Johnson and Vivus.","Full year 2022 operating loss of $58.4M vs $42.9M in 2021; R&D expense $39.8M, G&A $15.7M, commercial $9.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-038073","json":"https://secwatch.observer/filing/0001104659-23-038073.json","markdown":"https://secwatch.observer/filing/0001104659-23-038073.md","text":"https://secwatch.observer/filing/0001104659-23-038073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/tm2310783d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:12:43.210263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56f5b4ff970805a86085fec537ed38d5bdd0f0ec","claim":"Milestone Pharmaceuticals Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022, which also provided a clinical and corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}